Skip to content

Study on the Role of Tongue Coating Microbiota in Advanced Colorectal Cancer Patients with Kidney Deficiency Syndrome and the Intervention Effect of Bushen Jiedu Formula?

Study on the Role of Tongue Coating Microbiota in Advanced Colorectal Cancer Patients with Kidney Deficiency Syndrome and the Intervention Effect of Bushen Jiedu Formula?

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002113
Enrollment
Unknown
Registered
2025-11-04
Start date
2025-02-26
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer?

Interventions

TCM group:Kidney-Tonic Detoxifying Formula combined with basic therapy (chemotherapy and targeted therapy)
Control group:Conventional therapy (chemotherapy and targeted therapy)

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine?
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients with pathologically confirmed ??Stage IV (TNM classification) colorectal cancer??; 2.Meeting diagnostic criteria for ??Kidney Deficiency Syndrome?? in Traditional Chinese Medicine (TCM); 3.Aged ??18–75 years?? with an ??ECOG performance status (0–2)?? or ??Karnofsky Performance Status (KPS) =70??; 4.No use of ??antibiotics probiotics proton pump inhibitors (PPIs) or hormonal medications?? (known to significantly affect microbiota) within ??2 weeks prior to enrollment??; 5.??Good compliance?? with the ability to understand the study requirements and provide ??written informed consent??.

Exclusion criteria

Exclusion criteria: 1.Patients with ??concurrent primary tumors in other organs??; 2.Those with ??severe cardiovascular/cerebrovascular diseases major psychiatric disorders or cognitive impairment?? that may affect questionnaire responses; ??3.Pregnant or lactating women??; 4.Current participation or ??participation in other drug clinical trials within 4 weeks??.

Design outcomes

Primary

MeasureTime frame
Traditional Chinese Medicine Syndrome Scoring;

Secondary

MeasureTime frame
??Karnofsky Performance Status??;?Changes in immune cell CD4/CD8 ratios and validation factors before and after treatment?; ??Progression-Free Survival??; ??European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core - 30;Oral-Gut Microbiota?;Gut Microbial Metabolites?;

Countries

China

Contacts

Public ContactHuirong Zhu

No. 528 Zhangheng Road Pudong New Area Shanghai Shuguang Hospital?

zhu-huirong@163.com1891600300

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026